Home » Clinical Trials » Leukemia » NCT07074496
NCT07074496

An Open, Prospective, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Allogeneic Anti CD19 CAR-T Combined With a Novel Third-generation TKI Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Study Summary

This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.

Want to learn more about this trial?

Request More Info

Interventions

ThisCART19ADRUG
ThisCART19A is a new type CAR-T therapy for patients with ph+ ALL.
FludarabineDRUG
Fludarabine is used for lymphodepletion.
CyclophosphamideDRUG
Cyclophosphamide is used for lymphodepletion.
OlverembatinibDRUG
a third-generation TKI

Study Locations

FacilityCityStateCountry
The First Affiliated Hospital of Soochow University, Jiangsu Institute of HematologySuzhouJiangsuChina
The First Affiliated Hospital of Soochow University, Jiangsu Institute of HematologySuzhouJiangsuChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026